Form 4: OS Therapies Director John Ciccio Reports Stock Option Grant

OS Therapies Director John Ciccio reports 140,000 stock option grant.

Summary

• John Ciccio, a Director of OS Therapies Inc. (OSTX), reported changes in his beneficial ownership.
• He was granted options to purchase 140,000 shares of the issuer's common stock on October 21, 2025.
• The exercise price for these stock options is $1.8 per share.
• These options will vest in full on October 21, 2026, provided he continues to serve as a director of the issuer on that date.
• He indirectly owns 435,835 shares of common stock through Mill River Partners LLC, where he shares voting and investment power.
• He directly owns 20,000 shares of common stock.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. The grant of stock options to a director is a standard practice that aligns management's interests with shareholders, indicating continued commitment. However, it is a routine insider transaction and not indicative of specific operational or financial performance.

Positives

• The grant of 140,000 stock options to a director aligns management's interests with those of shareholders, incentivizing long-term performance.
• The director's continued equity stake demonstrates commitment to the company's future.

Risks

• The vesting of the 140,000 stock options is contingent upon John Ciccio's continued service as a director of OS Therapies Inc. on the one-year anniversary of the grant date.

Future Outlook

The grant of stock options with a one-year vesting period suggests an expectation of continued service from the director and aligns his future financial incentives with the company's performance over the coming year and beyond.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, common across all publicly traded companies. It reflects a standard compensation practice where directors receive equity-based incentives to align their interests with long-term shareholder value.

Comparison to Industry Standards

• The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industry, similar to compensation structures seen at companies like Amgen or Gilead Sciences, aiming to retain talent and align interests.
• The exercise price of $1.8 per share for the options is specific to OS Therapies Inc. and its current valuation, which would be compared against the company's stock price at the time of grant and its peers' option grants.

Related Party Transactions

• John Ciccio's indirect beneficial ownership of 435,835 shares of common stock is held through Mill River Partners LLC, where he serves on the board of managers and shares voting and investment power.

Stakeholder Impact

• Shareholders: The grant of stock options to a director can increase alignment between management and shareholder interests, potentially leading to better long-term performance.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The 140,000 stock options are scheduled to vest on October 21, 2026, contingent on John Ciccio's continued directorship.

Key Dates

Keywords

OS Therapies, OSTX, Form 4, beneficial ownership, stock options, director, John Ciccio, insider transaction, equity grant